N/A N=16 Expanded Hemodialysis Versus Online Hemodiafiltration
Dialysis Related Complication · Dialysis Hypotension · Hemodialysis-Induced Symptom
Primary: Medium Molecule Clearance — 53; 59.5 ml/min — p=0.4534
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=31 Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function
Hemodialysis · Kidney Failure, Chronic
Primary: QOL: Kidney Disease Quality of Life (KDQOL36) — 74; 72 score on a scale
N/A N=36 Study of HemoCare™ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD
End-Stage Renal Disease
Primary: Primary Safety Endpoint — 16.1; 11.6 Adverse Events per 100 Treatments
N/A N=16 Feasibility Study for Heparin-free Hemodialysis With the Dialyzer With Endexo™
Chronic Kidney Diseases · Patient Requiring Heparin Free Dialysis Treatments
Primary: The Primary Endpoint is the Number and Percent (%) of Successful Heparin-free HD Sessions for Each Subject in Each Circuit. — 2.4; 2.9 number of successful HD sessions
N/A N=172 Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
End Stage Renal Disease
Primary: Reduction Ratio of Lambda Immunoglobulin FLC at Week 24 — 32.156; 17.514 percentage ratio
N/A N=6 Intradialytic Drug Removal by Short-daily Hemodialysis
End Stage Renal Disease · Infection
Primary: Intradialytic Clearance of Levofloxacin, Gentamicin and Vancomycin in Patients Receiving Short-daily Hemodialysis — 7.2; 7.6 ml/min
N/A N=274 Theranova Randomized, Controlled, Trial (RCT) in China
Chronic Kidney Failure · Acute Kidney Failure
Primary: Reduction Ratio (RR) of Lambda Free Light Chains (λ FLC) — 36.02; 19.03 Reduction Ratio (%) — p=<0.0001
N/A N=1,431 Enhancing the Cardiovascular Safety of Hemodialysis Care (Dialysafe)
Kidney Failure · End Stage Renal Disease · Hypotension
Primary: Dialysis Session Stability — 0.202; 0.199; 0.172; 0.182 Proportion of sessions
Phase 1 N=119 HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
End Stage Renal Disease on Hemodialysis (Diagnosis)
Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…
Phase 3 N=48 A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease
End Stage Renal Failure on Dialysis
Primary: Patients' Adherence to Study Protocol — 22; 24; 19; 19 Participants
Phase 4 N=8 Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)
HIV-infected Participants With ESRD Undergoing Routine Hemodialysis
Primary: Percentatge of Doravirine Dialysis Extraction Ratio (ER) — 34.3 percentage of doravirine dialysis ER
Phase 4 N=4 Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
Hepatitis C · Hemodialysis · Nosocomial Infection
Primary: SVR - Sustained Virologic Response — 3; 0; 1; 0 Participants
Phase 4 N=8 Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis
Acute Kidney Failure
Primary: Ertapenem Transmembrane Clearance by Continuous Hemodialysis. — 10.4 mL/min
N/A N=15 Cerebral Blood Flow During Hemodialysis
Haemodialysis-induced Symptom
Primary: Change in CBF From Baseline (Before Start of the Hemodialysis Study Session), at 20 Minutes, and at the End of the Hemodialysis Study Session, Measured by [15O]H2OPET-CT…
Phase 2 N=52 Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension
Intra-dialytic Hypotension
Primary: Efficacy of Mannitol Administration in Reducing the Frequency of Intra-dialytic Hypotension (Decline in Systolic Blood Pressure) During the First Three Hemodialysis…
Phase 4 N=309 20070360 Incident Dialysis
Chronic Kidney Disease · Secondary Hyperparathyroidism
Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001
N/A N=13 Comparison Study of Daily Ultrafiltration and Twice-weekly Hemodialysis
End-stage Renal Disease
Primary: Mean Arterial Blood Pressure — 110; 95; 106 mm Hg
N/A N=86 Recovery Time and Affecting Factors in Hemodialysis Patients
Dialysis; Complications · Life Quality
Primary: Post-dialysis Recovery Time — 278.02 minutes
N/A N=11 A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients
End Stage Renal Disease (ESRD)
Primary: Clearance and Solute Removal Characteristics of Dialyzers — 354.1; 340.4; 361.8; 271.8 milliliters per minute (ml/min) — p=<0.001
N/A N=58 Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
Kidney Failure, Chronic · End-Stage Renal Disease
Primary: Primary Efficacy: Compare the Ability to Deliver the Clinically Prescribed Amount of Therapy in the Nocturnal Hemodialysis and Short Daily Hemodialysis Phases. — 90.9…
N/A N=19 Conventional Hemodialysis vs. Short Daily Hemodialysis (6 Days / Week) and Mechanisms of Blood Pressure Control
End Stage Renal Disease
Primary: Mean Systolic Blood Pressure Over the Third Month of Each Treatment Arm — 139; 142 mm Hg
N/A N=10 Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis
End-Stage Renal Disease
Primary: Safety as Evaluated by Rate and Severity of Treatment-emergent AEs (TEAEs) — 1; 0; 0; 0 Participants
N/A N=8 Sodium Chloride and Protein-Bound Toxin Removal in Hemodiafiltration
End-stage Renal Disease
Primary: Removal of Para-cresylsulfate — 42.0; 32.6; 33.6 percentage of reduction
N/A N=72 Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study
Renal Failure Chronic Requiring Hemodialysis
Primary: Percentage of Patients With Primary Patency — 48.2; 47.0; 30.6; 34.8 percentage of participants patent
Phase 2 N=7 Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients
End Stage Renal Disease
Primary: Mean Maximum Concentration (Cmax) of Ertapenem in Hemodialysis Patients — 663.1 mcg/ml
N/A N=25 An Open Label Study to Allow Patients Continuous Use of the HemoCare™ Hemodialysis System
End Stage Renal Disease
Primary: Number of Subjects With Safety Event — 20; 20; 5; 6 participants
N/A N=34 Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)
Diabetes Type 2
Primary: Hemoglobin A1c Levels — 7.1; 7.1 percent — p=0.67
N/A N=33 Ease of Use and Blood Clotting for the Gambro Polyflux HD-C4 Big Dialyzer
Chronic Kidney Failure
Primary: Ease of Use: Priming Blood Side — 139; 13; 13; 80 Number of Dialyzers
Phase 4 N=377 Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Sustained Virologic Response (SVR)Rate — 130; 72 participants — p=< 0.001
Phase 4 N=46 PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis
Hepatitis Viruses
Primary: Number of Participants With Sustained Virologic Response (SVR12) — 46 Participants